Physician profile
Mark A Major
NPI 1407032485
$9,576.66
in general payments reported to CMS, 2019-2025
33 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,396 · 2020: $915 · 2021: $1,509 · 2022: $915 · 2023: $1,148 · 2024: $1,373 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.38 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $2,701.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,181.80 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $1,104.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $960.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $689.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.77 | 2019-2024 | Jardiance |
| Pfizer INC. | $309.69 | 2020-2025 | |
| Memed US, INC. | $283.95 | 2024 | Memed Bv Calibrator |
| Abbvie INC. | $232.55 | 2020-2021 | |
| Glaxosmithkline, LLC. | $211.16 | 2020-2024 | Shingrix, Arexvy |
| Horizon Therapeutics Plc | $208.76 | 2020-2022 | |
| Abbott Laboratories | $186.57 | 2019-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $121.98 | 2021-2024 | Korlym |
| Redhill Biopharma INC. | $114.98 | 2020-2022 | |
| Viiv Healthcare Company | $96.07 | 2022-2023 | Apretude |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $80.12 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.55 | 2022 | |
| Janssen Pharmaceuticals, INC | $60.11 | 2019 | |
| Mylan Specialty L.P. | $46.93 | 2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $46.16 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $45.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.48 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $43.72 | 2022 | |
| Phadia US INC. | $43.24 | 2020-2024 | Immunocap |
| Smith+Nephew, INC. | $38.21 | 2021 | |
| Allergan, INC. | $37.73 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.93 | 2022 | |
| Zyla Life Sciences, INC. | $24.71 | 2019-2020 | |
| Global Blood Therapeutics, INC. | $23.98 | 2020 | |
| Nestle Healthcare Nutrition INC. | $19.92 | 2021 | |
| Dermira, INC. | $19.36 | 2020 | |
| Exact Sciences Corporation | $18.21 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $17.33 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Major listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.